About

Service

Advantage

Quarkmed Dynamics

Human Resources

Mail System

CTMS System

中EN

Quarkmed Dynamics

Quarkmed will keep moving forward, paying attention to hot topics in the industry, discussing the latest developments in the industry, and working with enterprises to promote new progress in medicine.
Partial Cooperative ClientsQuarkmed NewsTeam Style
Home>Quarkmed Dynamics

Quarkmed Enters International Strategic Partnership with NorthStar Medical Technologies as Its Registration Agent in China

2026-10-16

On October 14, 2026, NorthStar Medical Technologies, LLC ("NorthStar"), a U.S.-based producer of radioisotopes, entered into a strategic partnership with Quarkmed. The two parties will collaborate on the registration and filing of no-carrier-added actinium-225 (n.c.a. Ac-225) in China. Quarkmed will serve as NorthStars Registration Agent in China, providing Investigational New Drug (IND) applicati...

MORE
202026-08

Pharma PM Truth Session | Things Not Written in the SOPs

Some say the PM is just a progress-chaser.Some say the PM is the one who aligns all departments.And some, after a few years on the job, suddenly realize — the real work of a PM doesnt seem to be...

202026-08

Telix's New Vanguard: From a Single Radiopharmaceutical to a New Era

Background IntroductionOver the decade since targeted radioligand therapy (RLT) was first translated into clinical practice for prostate cancer, the global radiopharmaceutical field has long adhered t...

202026-05

Nectin-4 Radiopharmaceutical Development Hits the Accelerator!

Target Introduction RNA and Protein Expression of Nectin-4 (proteinatlas.org) Overview: Nectin-4 (Neural cell adhesion molecule-related molecule 4), also known as Poliovirus Receptor-Related Protein 4...

202026-05

In-Depth Analysis: The First B7-H3 Radiopharmaceutical Omburtamab's Failed Bid for FDA Approval

B7-H3: An IntroductionAs a hot target in tumor immunotherapy, B7-H3 has not only attracted fierce competition among multiple ADC (Antibody-Drug Conjugate) developers but has also garnered significant ...

202026-05

Quarkmed Invites You to SNMMI 2026: Exploring the Future of Nuclear Medicine

The 2026 SNMMI Annual Meeting will be held from May 30 to June 2, 2026, at the Los Angeles Convention Center. Quarkmed will be exhibiting at the event, and we warmly invite you to visit us at Booth 28...

192026-05

One Article to Understand the R&D Status of CXCR4-Targeted Nuclear Drugs!

CXCR4 Target and Related Nuclear Drugs IntroductionThe interactions between the CXCR4 receptor, its ligand CXCL12, and other interacting molecules, along with their roles in cell signaling. Image adap...

192026-05

How to Get Started with 225Ac Nuclear Drugs? This One is Enough!

Nuclear Drug: 225Ac-ch806Journal of Nuclear Medicine 2024; 00:1–7 This article analyzes the key data of preclinical studies on 225Ac nuclear drugs with examples. Published in December 2024 in th...

202026-04

Heyue Pharma: The Professional Choice for On-site Management of Radiopharmaceutical Clinical Trials

Heyue Pharma (hereinafter referred to as "Heyue"), a professional SMO under QuarkMed specializing in the field of radiopharmaceuticals, has been operating steadily for many years, consistently deliver...

232026-01

A New Breakthrough in B7-H3-Targeted Therapy: Frontier Exploration from ADCs to Radiopharmaceuticals

The B7-H3 ADC ExperienceIn 2020, Dr. Tongtong Xue co-founded Yilian Biology alongside a team of seasoned industry experts. As an innovative biotech company focused on the research and development of t...

123

Contact Us

010-86469979

Address：Ping An Fortune Center, Lize Financial Business District of Beijing

Follow the Wechat official account

Follow the Wechat official account